Germline Pathogenic Variants of Cancer Predisposition Genes in a multicentre Italian cohort of Pancreatic Cancer patients

Authors

Giulia Orsi

Published

September 1, 2024

Abstract

Germline BRCA1-2 test is routinely recommended in Pancreatic Cancer (PC) patients, due to its clinical-epidemiological relevance. Data on the prevalence of germline pathogenic variants (gPV) in other cancer predisposition and DNA Damage Repair (DDR) system-related genes in unselected PC cases are sparce in Italy. We assessed this prevalence in a multicentre cohort, to derive recommendations for PC patients.